News
Rare, serious alemtuzumab adverse events emerge
New reports reveal rare adverse events in the treatment of relapsing-remitting multiple sclerosis using alemtuzumab.
Conference Coverage
MRI Techniques Could Help Distinguish Between MS and Migraine
STOWE, VT—Some patients with migraine receive an inappropriate diagnosis of multiple sclerosis (MS). The two disorders share certain clinical and...
Video
Ari Green, MD
Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the...
Article
Siponimod May Benefit Patients With Secondary Progressive MS
Among patients with secondary progressive multiple sclerosis (MS), siponimod appears to decrease the risk of disability progression, according to...
Conference Coverage
High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
SAN DIEGO—Patients with relapsing-remitting multiple sclerosis (MS) who received high doses of the novel human endogenous retrovirus-W antagonist...
Conference Coverage
What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
SAN DIEGO—The monoclonal antibody alemtuzumab can be an effective treatment for people living with multiple sclerosis (MS), but the agent is also...
Conference Coverage
Patients With MS May Not Receive Appropriate Medicines From Primary Care Doctors
SAN DIEGO—Patients with multiple sclerosis (MS) who are treated by primary care physicians are significantly less likely to receive disease-...
Conference Coverage
Extended-Interval Dosing of Natalizumab Is Associated With Reduced PML Risk
SAN DIEGO—Among patients with multiple sclerosis (MS) who are positive for the John Cunningham virus (JCV), extended-interval dosing of...
Conference Coverage
MicroRNA Could Be a Biomarker of MS
SAN DIEGO—Absence of miR-219, a microRNA (miRNA), in CSF could be a biomarker of multiple sclerosis (MS), according to data presented at the...
Conference Coverage
Clean-Surfaced Nanocrystalline Gold May Promote Remyelination
SAN DIEGO—A novel therapy designed to promote the maturation and activation of myelin-producing oligodendrocytes is moving to phase II clinical...
Article
Natalizumab May Be Associated With Increased Disease Activity During Pregnancy
Women with relapsing-remitting multiple sclerosis (MS) who discontinue natalizumab treatment before pregnancy may have increased disease activity...
Article
Are Complementary and Alternative Treatments Effective for MS?
Cannabis extract, physical activity, and cognitive behavioral therapy are complementary and alternative medicines (CAMs) with the strongest...
News
Frankincense extract may reduce disease activity in relapsing-remitting MS
Safety results and potential efficacy point to possible future clinical development.
News
Siponimod trial ‘first’ to show delayed disability in secondary progressive MS
But the absolute difference in the rate of confirmed disability progression versus placebo was small.
News
MRI finds PML in some natalizumab-treated patients despite negative CSF, no symptoms
Correlation also observed between viral load and lesion volume.
Article
MS Medication Withdrawn Because of Safety Concerns
Citing concerns about safety, Biogen and AbbVie announced March 2 that they will be withdrawing daclizumab (Zinbryta) from worldwide markets....
Conference Coverage
Alemtuzumab-induced autoimmunity: getting closer to answers
Researchers are getting closer to identifying MS patients more susceptible to secondary autoimmunity after alemtuzumab treatment.
Conference Coverage
- MRI Techniques Could Help Distinguish Between MS and Migraine
- High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
- What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
- Patients With MS May Not Receive Appropriate Medicines From Primary Care Doctors
- Extended-Interval Dosing of Natalizumab Is Associated With Reduced PML Risk
Multimedia
Question 1 of 5
